Recruiting talent in response to expanded development activities
First written in FY2017. 4 of 10 entries say "Advanced", first in FY2020. Latest entry: FY2026.
The whole theme swung hardest in 2026: 3 of 34 companies on the "Worse" side.
7 other companies' latest entry also says "Other".
- FY2026Continued challenges in increasing headcount and securing talentAnnual report
「The Group is currently operating as a small organization, but securing personnel will be important for future growth. The Group will continue to focus on securing the necessary talent appropriately and sufficiently to maintain sustainable growth.」
Although consolidated headcount increased from 29 in the previous fiscal year to 33, securing the necessary talent remains an ongoing challenge given the Group's small organizational structure. - FY2024Decrease in headcount and transfer of research and development functions associated with organizational restructuringAnnual report
「The number of employees decreased by 36 from the end of the previous consolidated fiscal year, primarily because SanBio, Inc., a subsidiary of the Company, implemented workforce reductions as part of an organizational restructuring.」
Consolidated headcount decreased by 36 from 65 to 29. In addition to workforce reductions at SanBio, Inc., research and development and other functions changed from SanBio, Inc. to the reporting company. - FY2024-Q3RestatedAnnual report
「During the nine-month consolidated period, the Group carried out an organizational restructuring as part of efforts to improve management and organizational efficiency, specifically implementing workforce reductions at its U.S. subsidiary SanBio, Inc. As a result, the Group's main research and development base has changed from SanBio, Inc. to the Company.」
The implementation status of the organizational restructuring described in the previous quarter, including workforce reductions at the U.S. subsidiary and the transfer of the main research and development base to the reporting company, has been reaffirmed. - FY2024-Q2AdvancedAnnual report
「During the six-month consolidated period, the Group carried out an organizational restructuring as part of efforts to improve management and organizational efficiency, specifically implementing workforce reductions at its U.S. subsidiary SanBio, Inc. As a result, the Group's main research and development base will change from SanBio, Inc. to the Company.」
As part of the organizational restructuring, workforce reductions were implemented at U.S. subsidiary SanBio, Inc., and plans to transfer the main research and development base from that company to the reporting company took concrete shape. - FY2023Decrease in headcount associated with organizational restructuringAnnual report
「The number of employees decreased by 24 from the end of the previous consolidated fiscal year, primarily because SanBio, Inc., a subsidiary of the Company, implemented workforce reductions as part of an organizational restructuring.」
Consolidated headcount decreased by 24 from 89 to 65, with workforce reductions associated with organizational restructuring at SanBio, Inc. cited as the reason. - FY2022AdvancedAnnual report
「Employees (people) 32 43 74 85 89」
Consolidated headcount increased from 85 in the previous consolidated fiscal year to 89, while research and development headcount reached 61. The disclosure describes an expansion in workforce capacity supporting development, marketing authorization applications and the post-marketing framework. - FY2021AdvancedAnnual report
「The number of employees in the Company-wide common segment increased by 9 from the end of the previous consolidated fiscal year, primarily because the business and administrative divisions were expanded to establish the post-marketing management framework for the regenerative cell medicine SB623.」
To establish the post-marketing framework for SB623, Company-wide common headcount increased by 9 from the end of the previous fiscal year, and the business and administrative divisions were expanded. Consolidated headcount was 85. - FY2020AdvancedAnnual report
「The number of employees increased by 31 from the end of the previous consolidated fiscal year, primarily to establish a stable post-marketing supply system for the regenerative cell medicine SB623.」
Consolidated headcount increased by 31 from the end of the previous fiscal year to 74, confirming the expansion of personnel to establish a stable post-marketing supply system. - FY2019RestatedAnnual report
「The Company will continue to work to secure an appropriate and sufficient workforce in line with the acceleration of development, establishment of a post-marketing framework, expansion of target diseases and progress in its pipeline.」
The policy of securing personnel in line with accelerated development, establishment of a post-marketing framework, expansion of indications and pipeline progress has been reaffirmed. - FY2017First statedAnnual report
「The Company will continue to work to secure an appropriate and sufficient workforce in line with the acceleration of development, expansion of target diseases and progress in its pipeline.」
The Company has outlined a policy of securing personnel in line with accelerated development and the expansion of target diseases and its pipeline.